Stay updated with breaking news from Yael mauer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists has been revolutionary. ....
Yael Mauer, MD, MPH, discusses the patient population who benefits most from interventions with glucagon-like peptide-1 (GLP-1) therapies and explores the underlying mechanisms at work. ....